Solstice Neurosciences
Date | Investors | Amount | Round |
---|---|---|---|
$8.0m | Early VC | ||
$85.0m | Series B | ||
$35.7m Valuation: $35.7m | Acquisition | ||
Total Funding | $93.0m |
Related Content
Recent News about Solstice Neurosciences
EditSolstice Neurosciences, a subsidiary of US WorldMeds, operates in the specialty pharmaceutical sector, focusing on developing, licensing, and marketing healthcare products that address unmet medical needs. The company primarily serves patients with neurological conditions, offering treatments that improve quality of life and patient outcomes. Solstice Neurosciences operates within the broader pharmaceutical market, targeting niche segments with high demand for innovative therapies. The business model revolves around the development and commercialization of proprietary drugs, generating revenue through product sales and licensing agreements. By maintaining a strong pipeline of new products and leveraging strategic partnerships, Solstice Neurosciences aims to sustain growth and deliver value to patients, employees, and shareholders. The company emphasizes a culture of integrity, creativity, and action, ensuring sustainable operations and a commitment to community health.
Keywords: specialty pharmaceuticals, neurological treatments, patient care, drug development, licensing, commercialization, innovation, healthcare products, niche market, strategic partnerships.